Sitagliptin on carotid intima-media thickness in type 2 diabetes and hyperuricemia patients: a subgroup analysis of the PROLOGUE study
| العنوان: | Sitagliptin on carotid intima-media thickness in type 2 diabetes and hyperuricemia patients: a subgroup analysis of the PROLOGUE study |
|---|---|
| المؤلفون: | Jianmin Tang, Wei Deng, Dazhi Ke, Yipin Zhao, Qingwei Chen, Huawei Wang, Yingying Ji, Li Xiao, Guoxing Li, Zebin Lin, Jiaojiao Yang |
| المصدر: | Therapeutic Advances in Chronic Disease Therapeutic Advances in Chronic Disease, Vol 12 (2021) |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | medicine.medical_specialty, Prologue, type 2 diabetes mellitus, Medicine (miscellaneous), 030209 endocrinology & metabolism, Subgroup analysis, RM1-950, Type 2 diabetes, hyperuricemia, 030204 cardiovascular system & hematology, Gastroenterology, sitagliptin, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, PROLOGUE study, Medicine, Hyperuricemia, cardiovascular diseases, intima-media thickness, Original Research, business.industry, Type 2 Diabetes Mellitus, nutritional and metabolic diseases, medicine.disease, Intima-media thickness, Sitagliptin, cardiovascular system, Therapeutics. Pharmacology, business, medicine.drug |
| الوصف: | Background and Aims: Studies have shown that dipeptidyl peptidase-4 (DDP-4) inhibitors have anti-atherosclerotic effects. However, in the PROLOGUE study, sitagliptin failed to slow the progression of carotid intima-media thickness (CIMT) relative to conventional therapy. We conducted a post hoc analysis of the PROLOGUE study and compared the effects of sitagliptin and conventional therapy on changes in CIMT in subgroups with or without hyperuricemia. Methods: The PROLOGUE study was a randomized controlled trial of 442 patients with type 2 diabetes mellitus (T2DM). Patients were randomized to receive sitagliptin added therapy or conventional therapy. Based on the serum uric acid levels of all study populations in the PROLOGUE study, we divided them into hyperuricemia subgroup ( n = 104) and non-hyperuricemia subgroup ( n = 331). The primary outcome was changed in carotid intima-media thickness (CIMT) parameters compared with baseline during the 24 months treatment period. Results: In the hyperuricemia subgroup, compared with the conventional therapy group, the changes in the mean internal carotid artery (ICA)-IMT and max ICA-IMT at 24 months were significantly lower in the sitagliptin group [−0.233 mm, 95% confidence interval (CI) (−0.419 to 0.046), p = 0.015 and −0.325 mm, 95% CI (−0.583 to −0.068), p = 0.014], although there was no significant difference in the common carotid artery CIMT. Conclusion: The results of our analysis indicated that sitagliptin attenuated the progression of CIMT than conventional therapy in T2DM and hyperuricemia patients. |
| تدمد: | 2040-6223 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4eb7f1248504f06073e3b95b1da94b75 https://pubmed.ncbi.nlm.nih.gov/34221308 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....4eb7f1248504f06073e3b95b1da94b75 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20406223 |
|---|